- Research article
- Open Access
The effect of formulation vehicles on the in vitro percutaneous permeation of ibuprofen
© Stahl et al; licensee BioMed Central Ltd. 2011
- Received: 13 July 2011
- Accepted: 14 December 2011
- Published: 14 December 2011
The transdermal application of substances represents an elegant approach to overcome side effects related to injections or oral treatment. Due to benefits like a constant plasma level, no pain during application and a simple therapeutic regime, the optimization of formulations for transdermal drug delivery has gained interest in the last decades. Ibuprofen is a non-steroidal anti-inflammatory compound which is nowadays often used transdermally. The objective of this work was to conduct a study on the effect of different 5% ibuprofen containing formulations (Ibutop® cream, Ibutop® gel, and ibuprofen solution in phosphate buffered saline) on the in vitro-percutaneous permeation of ibuprofen through skin to emphasise the importance of the formulation on percutaneous permeation and skin reservoir.
The permeation experiments were conducted in Franz-type diffusion cells according to OECD guideline 428 with 2 mg/cm2 ibuprofen formulation on each skin sample. Ibuprofen was analysed in the receptor fluid and extracted skin samples by UV-VIS high-performance liquid-chromatography at 238 nm. The plot of the cumulative amount of ibuprofen permeated versus time was employed to calculate the apparent permeability coefficient, the maximum flux and the lagtime, all of which were statistically analysed by One-way ANOVA.
Although ibuprofen permeation out of the gel increases rapidly within the first four hours, the cream produced the highest ibuprofen delivery through the skin within 28 hours, followed by the solution and the gel. A significant shorter lagtime was found after gel treatment compared with the cream and the solution. After 28 hours 59% of the applied ibuprofen was found in the receptor fluid of the cream treated samples, 26% in the solution treated samples and 21% in the samples treated with the gel. Fourfold higher ibuprofen reservoirs were found in the solution and gel treated skin samples compared to the cream treated skin samples.
The present study demonstrates the importance of the formulation on transdermal drug delivery of ibuprofen and emphasises the differences of drug storage within the skin due to the formulation. Thus, it is a mistaken assumption that formulations comprising the same drug amount are equivalent regarding skin permeability.
- Stratum Corneum
- Skin Sample
- Permeation Enhancer
- Receptor Chamber
The skin with a surface area of approximately 2 m2 in human beings represents the largest organ of the body and protects the latter from the intrusion of environmental substances and transepidermal water loss . However, the main skin barrier, the stratum corneum, is permeable for a small percentage of compounds with moderate oil-water partition coefficients, small molecular weights and low melting points . The stratum corneum is a complex structure comprising hydrophilic "dry" corneocytes embedded in a lipid matrix predominantly consisting of a mixture of ceramides, cholesteryl and free fatty acids . Compounds on the skin surface can pass through the stratum corneum by different ways. Beside the intercellular way through the lipid matrix between the corneocytes, hair follicles and sebaceous glands are likely to be employed as diffusion shunt ways . To facilitate transdermal drug delivery for substances without permeation or to increase the amount of substance with poor permeation profiles many studies have been conducted (reviewed in ). Beside chemical permeation enhancers such as alcohols or terpenes [4, 5] which interact with the stratum corneum architecture or lipid composition, physical enhancers like iontophoresis, sonophoresis or microneedles have been produced to overcome the skin barrier [6–9]. Likewise, the formulation in which a compound is applied onto the skin determines the rate of percutaneous permeation , as thermodynamic activities e.g. can vary from formulation to formulation. Although in vivo- and in vitro-s tudies demonstrate the vehicle dependence of the permeation profile of ibuprofen, the variety of ingredients used can barely be used to predict ibuprofen delivery out of these formulations [11, 12]. Consequently, comparative studies with effective formulations are necessary to characterise the effectiveness of the marketed products such as creams, gels, sprays, mousses and ointments.
Thus, the object of the present study was to examine the in vitro permeation profile of ibuprofen out of two marketed formulations and ibuprofen solution, all of which contained 5% ibuprofen, through skin to show the impact of the vehicle on transdermal drug delivery. Moreover, the ibuprofen content in the skin samples was measured to investigate whether the formulation determines the drug reservoir within the skin.
All reagents used for the present study were of the highest purity available. The salts used for the buffer production were obtained from Merck (Darmstadt, Germany) and methanol was obtained from Applichem (Darmstadt, Germany).
The skin was obtained from udders of Holstein Friesian cows at the slaughterhouse. In brief, skin flaps were removed from udders immediately after slaughter. The flaps were washed with cold water before they were stored at -20°C until use (maximum 3 weeks). Prior to the experiment, the skin flaps were defrosted and an electrical dermatome (Zimmer, Eschbach, Germany) was employed to obtain 500 μm (± 100 μ m) thick split skin samples.
Ingredients of topical formulations containing ibuprofen 5%
Sodium methyl hydroxybenzoate
Phosphate buffered saline (pH 7.4)
Medium chain triglycerides
Medium chain triglycerides
Macrogol stearate 1500
Macrogol stearate 5000
In-vitro permeation experiments
The permeation experiments were conducted in skin samples of four to six animals in duplicate under non-occlusive conditions according to OECD guideline 428 . Prior to the experiment both the skin samples were cut into pieces of 4 cm2 which were incubated in PBS for 30 minutes. They were mounted between the donor and the receptor chamber of Franz-type diffusion cells (with the stratum corneum pointing to the donor chamber), all of which were maintained at 32°C by a water bath. The receptor chambers were filled with 12 ml sonicated PBS and stirred continuously with a magnetic bar (500 rpm). Just before administration of the different formulations on the membrane surface a 400 μl sample was withdrawn from the receptor chamber. Additional samples were taken at the following times: 0.5, 1, 2, 3, 4, 6, 22, 24, 26 and 28 hours. After each sample withdrawal the receptor chamber was refilled with 400 μl PBS.
Ibuprofen measurement in the skin samples
The amount of ibuprofen in the skin samples was determined after completion of the diffusion experiment. Therefore, the skin samples were removed from the diffusion cells and rinsed with cold water. A biopsy-punch with a diameter of 6 mm was employed to obtain a skin biopsy from the diffusion area, which was shaken with 10 μl H2SO4 (2 N) and 800 μl methanol for 30 minutes. After 24 hours incubation at 4°C the supernatant was collected and 190 μl McIlvaine citrate buffer (pH 2.2; 1 l contains 20.8 g citric acid anhydrous, 0.4 g Na2HPO4 × 2H2O and deionised water) were added. The recovery was approximately 85-90%.
Ibuprofen in both the receptor medium samples and the skin samples was analysed by a validated UV-VIS high-performance liquid-chromatography methodology using a Merck LiChroCART 125-4 Lichrospher 100 RP18e (5 mm) column (Darmstadt, Germany) and a model 168 UV-VIS detector from Beckman (Fullerton, CA, USA) at 238 nm . The mobile phase which was a 80:20 (v/v) mixture of methanol and McIlvaine citrate buffer (pH 2.2) was pumped by a 116 pump from Beckman (1.5 ml/min). The content of ibuprofen was determined using the external standard method. The limit of quantification was 200 ng/ml and the limit of detection was 100 ng/ml. The recovery results in the receptor chamber are expressed as percentage recovery of the applied amount of ibuprofen. The amount of ibuprofen found in the skin samples is expressed as "skin absorption" in μg/cm2.
The plot of the cumulated amount of ibuprofen versus time was employed for the calculation of the apparent permeability coefficients (Papp) according to Niedorf et al. 2008  as well as for the determination of the maximum flux Jmax and the lagtime. Values from replicated experiments (2 replicates per formulation) in skin from the same individual were used as average. Differences in the permeation parameters (Papp, Jmax, lagtime, and recovery) were evaluated using One-way ANOVA (analysis of variance) followed by Tukey's multiple comparison test (GraphPad Prism 4.01 (GraphPad Software Inc., San Diego, USA)) with a significance level of p < 0.05.
Skin permeation parameters
Jmax (μ g/cm2/h)
Skin absorption (μ g/cm2)
Ibutop ® gel
21 ± 5a
50 ± 23
0.0 ± 0.2ac
239 ± 159
Ibutop ® cream
59 ± 8
65 ± 15
1.3 ± 0.6
57 ± 25
26 ± 8b
42 ± 16
1.3 ± 0.8
264 ± 192
The present study was conducted to investigate the influence of the galenic formulation on the percutaneous permeation of ibuprofen and its storage within the skin. Although the examined formulations comprised the same amount of ibuprofen (5% w/w), considerable differences in the permeation profiles were determined comparable with Hadgraft et al. (2003) . The cream formulation was the most efficient vehicle for ibuprofen permeation through the skin as it reached twofold to threefold higher amounts of ibuprofen in the receptor chamber within 28 hours. The permeation of the ibuprofen solution ranged between the permeation of the cream and of the gel which offered a lower ibuprofen delivery through the skin. Despite a sharp initial increase in the permeation of ibuprofen out of the latter, only a small percentage of ibuprofen was delivered into the receptor fluid after application of the gel formulation over time. It has to be taken into consideration that ibuprofen represents a non-steroidal anti-inflammatory drug which is predominantly taken due to its rapid pain relief and anti-inflammatory action. Thus, a high percentage of permeated ibuprofen results in the best clinical benefits. It is likely, that the application of the gel leads to a fast and effective ibuprofen concentration in the organism, whereas the data of the present in vitro study do not inform about effective plasma levels after topical administration in vivo. It has to be discussed whether the sharp incline of the ibuprofen permeation out of the gel is prejudicial to the patient compared to a steady ibuprofen permeation in the first hours after administration. Since high amounts of ibuprofen were found to be in the skin after 28 hours gel treatment, it can be supposed that, on condition that the comparatively low permeation is sufficient to produce efficacious blood levels, the gel offers advantages concerning a long-term treatment. Thus, the skin supplies the body continuously with ibuprofen without the need of a follow-up treatment, even after removal of the remained formulation on the skin surface.
The fact that different formulations comprising ibuprofen as active compound impact the amount of transdermal drug delivery confirms findings of Hadgraft et al. 2003  and is likely to be explained by partition and diffusion phenomena. Therefore, 5% ibuprofen containing formulation applied onto the skin can result in unpredictable ibuprofen fluxes, which have to be compared to effective therapeutics. Furthermore, the drug reservoir within the skin is considerably determined by the galenic formulation. Surprisingly, the topical application of the self-made ibuprofen solution as control resulted in a permeation rate in the middle of the marketed products, despite the lacking of supplementation of permeation enhancers like 2-propanol or medium chain triglycerides, all of which interact with the stratum corneum.
The present investigation demonstrates the importance of vehicle formulation on transdermal drug delivery of ibuprofen and highlights the differences of drug reservoirs within the skin due to different galenics.
Bettina Blume is gratefully acknowledged for skin acquisition and Theiss Wystemp for his technical help.
- Hadgraft J: Skin, the final frontier 32. IntJPharm. 2001, 224: 1-18.Google Scholar
- Magnusson BM, Anissimov YG, Cross SE, Roberts MS: Molecular size as the main determinant of solute maximum flux across the skin 4. JInvest Dermatol. 2004, 122: 993-999. 10.1111/j.0022-202X.2004.22413.x.View ArticleGoogle Scholar
- Lampe MA, Burlingame AL, Whitney J, Williams ML, Brown BE, Roitman E, Elias PM: Human stratum corneum lipids: characterization and regional variations 3. JLipid Res. 1983, 24: 120-130.Google Scholar
- Thong HY, Zhai H, Maibach HI: Percutaneous penetration enhancers: an overview. Skin Pharmacol Physiol. 2007, 20: 272-282. 10.1159/000107575.View ArticlePubMedGoogle Scholar
- Williams AC, Barry BW: Skin absorption enhancers. Crit Rev Ther Drug Carrier Syst. 1992, 9: 305-353.PubMedGoogle Scholar
- Singh J, Singh S: Transdermal iontophoresis: effect of penetration enhancer and iontophoresis on drug transport and surface characteristics of human epidermis. Curr Probl Dermatol. 1995, 22: 179-183.View ArticlePubMedGoogle Scholar
- Srinivasan V, Higuchi WI, Sims SM, Ghanem AH, Behl CR: Transdermal iontophoretic drug delivery: mechanistic analysis and application to polypeptide delivery. J Pharm Sci. 1989, 78: 370-375. 10.1002/jps.2600780506.View ArticlePubMedGoogle Scholar
- Escobar-Chavez JJ, Bonilla-Martinez D, Villegas-Gonzalez MA, Molina-Trinidad E, Casas-Alancaster N, Revilla-Vazquez AL: Microneedles: A Valuable Physical Enhancer to Increase Transdermal Drug Delivery. J Clin Pharmacol.Google Scholar
- Henry S, McAllister DV, Allen MG, Prausnitz MR: Microfabricated microneedles: A novel approach to transdermal drug delivery. J Pharm Sci. 1999, 88: 948-PubMedGoogle Scholar
- Horhota ST, Fung HL: Percutaneous nitroglycerin absorption in rats 1. JPharmSci. 1979, 68: 608-612.Google Scholar
- Hadgraft J, Whitefield M, Rosher PH: Skin penetration of topical formulations of ibuprofen 5%: an in vitro comparative study. Skin Pharmacol Appl Skin Physiol. 2003, 16: 137-142. 10.1159/000069759.View ArticlePubMedGoogle Scholar
- Herkenne C, Naik A, Kalia YN, Hadgraft J, Guy RH: Ibuprofen Transport into and through Skin from Topical Formulations: In Vitro-In Vivo Comparison 1. J Invest Dermatol. 2006Google Scholar
- OECD: OECD GUIDELINE FOR THE TESTING OF CHEMICALS (428): Skin absorption in vitro method. 2004View ArticleGoogle Scholar
- Stahl J, Niedorf F, Kietzmann M: The correlation between epidermal lipid composition and morphologic skin characteristics with percutaneous permeation: an interspecies comparison of substances with different lipophilicity. J Vet Pharmacol Ther. 2011, 34: 502-507. 10.1111/j.1365-2885.2010.01246.x.View ArticlePubMedGoogle Scholar
- Niedorf F, Schmidt E, Kietzmann M: The automated, accurate and reproducible determination of steady-state permeation parameters from percutaneous permeation data. Altern Lab Anim. 2008, 36: 201-213.PubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.